Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.57 |
| ▸ | MAOB | P27338 | 9/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.44 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467074 | 1.00 | MAOA (0.57) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2534095 | 0.87 | MAOA (0.54) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2203216 | 0.86 | MAOA (0.60) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL21910885 | 0.85 | MAOA (0.53) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2029147 | 0.84 | MAOA (0.51) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2531605 | 0.83 | MAOB (0.54) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL17103203 | 0.83 | MAOA (0.57) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL16953003 | 0.83 | CYP2C19 (0.46) | MAOAMAOBALDH1A1CYP3A4HPGD | |
| SCHEMBL16952743 | 0.83 | CYP2C19 (0.43) | MAOAMAOBTDP1ALDH1A1CYP3A4 | |
| SCHEMBL6493712 | 0.82 | ALDH1A1 (0.57) | MAOAMAOBNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508239-B2 | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures | H. LUNDBECK A/S (DK) | 2025-12-30 | — | — | US | disclosed |
| EP-4007571-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H LUNDBECK AS (DK) | 2025-06-18 | — | — | EP | disclosed |
| EP-4241843-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2025-05-21 | — | — | EP | disclosed |
| US-12258305-B2 | Alcohol derivatives as Kv7 potassium channel openers | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| US-20230303486-A1 | CYCLOBUTYL-UREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-28 | — | — | US | disclosed |
| EP-4241843-A2 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2023-09-13 | — | — | EP | disclosed |
| EP-4241843-A2 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2023-09-13 | — | — | EP | disclosed |
| CN-116589375-A | Alcohol derivatives as Kv7 potassium channel openers | H.隆德贝克有限公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3755684-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| EP-3755684-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| US-6458803-B1 | COMPOSITIONS AND METHODS FOR TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. PREFERRED TERTIARY-HETEROALKYLAMINE COMPOUNDS ARE SUBSTITUTED N-PHENYL-N-HETEROARALKYL AMINOALCOHOLS. A PREFERRED SPECIFIC | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6455519-B1 | TREATING ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | disclosed |
| US-6451830-B1 | Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-09-17 | — | — | US | disclosed |
| US-6451823-B1 | Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-09-17 | — | — | US | disclosed |
| US-6448295-B1 | TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN | G.D. SEARLE & CO. | 2002-09-10 | — | — | US | disclosed |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-08-29 | — | — | US | disclosed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0197868-B1 | PROCESS FOR THE PREPARATION OF DICHLOROTRIFLUOROETHOXY AND ETHYLTHIOAROMATIC DERIVATIVES | RHONE-POULENC CHIMIE (FR) | 1988-05-18 | — | — | EP | disclosed |
| US-4256749-A | HYPOTENSIVE AGENTS, CIRCULATION | BAYER AKTIENGESELLSCHAFT (DE) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303486-A1 | CYCLOBUTYL-UREA DERIVATIVES | KCNA4, KCNMB4, KCNA7 | MAOA 1873/4885MAOB 872/4885NPC1 4063/4885 |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, DBI | MAOA 2106/4885MAOB 1480/4885NPC1 7/4885 |
| US-12508239-B2 | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures | KCNN3, KCNN1, KCNN2 | MAOA 698/4885MAOB 1372/4885NPC1 385/4885 |
| US-12258305-B2 | Alcohol derivatives as Kv7 potassium channel openers | KCNA7, KCNK17, KCNQ1 | MAOA 1799/4885MAOB 1994/4885NPC1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.